Hoth Therapeutics, Inc. (HOTH)
After hours:
| Previous close | 0.7565 |
| Open | 0.7330 |
| Bid | 0.7158 x 100 |
| Ask | 0.7949 x 100 |
| Day's range | 0.7330 - 0.7600 |
| 52-week range | 0.5800 - 1.7300 |
| Volume | |
| Avg. volume | 3,724,189 |
| Market cap | 5.185M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. In a recent study using Alzheimer's model mice treated with varying doses of HT-ALZ, significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive functi
- PR Newswire
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
- PR Newswire
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing next-generation therapies for unmet medical needs, is excited to announce positive data from the treatment of epidermal growth factor receptor inhibitor (EGFRI) associated papulopustular eruptions (PPEs) with its novel therapeutic HT-001. During this first-of-its-kind human patient case, the patient was able to cease treatment after just one week due to the rapid and successful resolution of symptoms, marki
